id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S17713 R74734 |
Bjorkstedt - BZDs, 2025 | Major congenital anomalies (excluding minor anomalies according to the EUROCAT guidelines) | during pregnancy (anytime or not specified) excluded | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes BZD Coexposure: Not specified |
2.11 [1.17;3.81] excluded (exposition period) |
16/199 -/5,594 | - | 199 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S17044 R75082 |
Chuang - BZDs, 2024 | Major congenital malformations | 1st trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes BZD Coexposure: Not specified | 1.03 [0.98;1.09] | 1,704/50,272 75,526/2,632,733 | 77,230 | 50,272 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S16749 R70376 |
The NAAED - Clonazepam, 2023 | Major congenital malformations | 1st trimester | prospective cohort | unexposed, disease free | Adjustment: No BZD Coexposure: No (among antiseizure medications) | 2.25 [0.64;7.88] C | 3/120 15/1,330 | 18 | 120 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15405 R63477 |
Lee - Alprazolam, 2022 | Malformations | 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No BZD Coexposure: Not specified | 1.28 [0.37;4.47] C | 3/82 17/591 | 20 | 82 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15381 R64465 |
Noh - BZDs, 2022 | Overall major congenital malformations | 1st trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes BZD Coexposure: No (among psychiatric (ATD and/or psychotropics) medications) | 1.11 [1.06;1.15] | 2,322/35,385 156,896/3,053,381 | 159,218 | 35,385 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15447 R64482 |
Szpunar - BZDs, 2022 | Major malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: Yes BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) Indication BZD: Psychiatric diseases (depression, anxiety, ...) | 0.92 [0.35;2.41] | 5/156 32/925 | 37 | 156 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15446 R63531 |
Zanisi - BZDs, 2022 | Malformations | during pregnancy (anytime or not specified) excluded | cohort | unexposed (general population or NOS) | Adjustment: No BZD Coexposure: No (among psychiatric (ATD and/or psychotropics) medications) |
1.04 [0.17;6.33] excluded (exposition period) |
2/99 3/158 | 5 | 99 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15330 R64449 |
Ban - Diazepam (Other indications) (Controls unexposed, disease free), 2014 | Any major congenital anomalies (excluding genetic anomalies and anomalies attributed to known teratogens, e.g. anomalies due to maternal infections and fetal alcohol syndrome) | 1st trimester | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: Yes BZD Coexposure: No (among psychiatric (ATD and/or psychotropics) medications) Indication BZD: Psychiatric diseases (depression, anxiety, ...) |
1.02 [0.63;1.64] excluded (control group) |
31/1,159 9,368/351,785 | 9,399 | 1,159 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15327 R64450 |
Ban - Diazepam (Other indications) (Controls unexposed, sick), 2014 | Any major congenital anomalies (excluding genetic anomalies and anomalies attributed to known teratogens, e.g. anomalies due to maternal infections and fetal alcohol syndrome) | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes BZD Coexposure: No (among psychiatric (ATD and/or psychotropics) medications) Indication BZD: Psychiatric diseases (depression, anxiety, ...) | 0.99 [0.61;1.61] | 31/1,159 518/19,193 | 549 | 1,159 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15621 R64491 |
Veiby - Clonazepam (Mixed indications), 2014 | Major malformations | throughout pregnancy | population based cohort retrospective | unexposed, disease free | Adjustment: Yes BZD Coexposure: No (among antiseizure medications) | 0.65 [0.16;2.62] | 2/113 22,371/771,412 | 22,373 | 113 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15587 R64459 |
Källén - BZDs, 2013 | Relatively severe malformations | early pregnancy | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes BZD Coexposure: Not specified | 1.11 [0.92;1.35] | 108/2,537 49,499/1,575,847 | 49,607 | 2,537 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15404 R63470 |
Yamane - Etizolam, 2011 | Congenital anomalies | early pregnancy | cohort | unexposed (general population or NOS) | Adjustment: No BZD Coexposure: Not specified | 0.77 [0.24;2.42] | 6/202 -/- | - | 202 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15335 R63158 |
Oberlander - BZDs, 2008 | Major congenital anomalies | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No BZD Coexposure: No (among psychiatric (ATD and/or psychotropics) medications) | 1.02 [0.71;1.46] C | 31/968 3,369/107,320 | 3,400 | 968 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15535 R64456 |
Czeizel - Diazepam, 2003 | Major congenital anomalies | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: Yes BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) Matched | 1.20 [1.10;1.40] | -/- 22,874/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15322 R64481 |
Ornoy - BZDs, 1998 | Infants with major anomalies | at least 1st trimester | prospective cohort | unexposed, disease free | Adjustment: No BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) | 1.20 [0.50;2.80] | 11/355 10/382 | 21 | 355 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15310 R64464 |
Laegreid a - BZDs, 1992 | Major malformations | throughout pregnancy | prospective cohort | unexposed, disease free | Adjustment: No BZD Coexposure: No (among psychiatric (ATD and/or psychotropics) medications) Indication BZD: Psychiatric diseases (depression, anxiety, ...) | 1.75 [0.10;29.93] C | 1/17 1/29 | 2 | 17 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15424 R64454 |
Bracken - Diazepam, 1981 | Major congenital malformations | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: No BZD Coexposure: Not specified Indication BZD: Psychiatric diseases (depression, anxiety, ...) | 2.77 [1.67;4.61] C | 34/61 1,336/4,277 | 1,370 | 61 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15380 R63371 |
Greenberg - BZDs, 1977 | Congenital abnormalities (minor abnormalities excluded) | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: No BZD Coexposure: Not specified | 1.22 [0.70;2.11] C | 29/53 800/1,605 | 829 | 53 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15440 R63514 |
Kullander - Chlordiazepoxide, 1976 | Minor and major malformations | 1st trimester | nested case control | unexposed (general population or NOS) | Adjustment: No BZD Coexposure: Not specified | 0.56 [0.26;1.23] C | 7/89 744/5,664 | 751 | 89 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15458 R63559 |
Hartz - Chlordiazepoxide, 1975 | Malformed child (with uniform rates, thus excluding inguinal hernia, clubfoot, pectus excavatum, cleft gum and abnormal hand or fingers other tha polydactyly or syndactyly) | early pregnancy | prospective cohort | unexposed (general population or NOS) | Adjustment: Yes BZD Coexposure: Not specified | 0.80 [0.40;1.60] | 11/257 2,179/48,412 | 2,190 | 257 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 17 studies | 1.11 [1.03;1.19] | 317,615 | 91,826 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Other indications) (Controls unexposed, sick; 2: Mixed indications;
Asymetry test p-value = 0.7353 (by Egger's regression)
slope=0.0810 (0.0247); intercept=0.1331 (0.3864); t=0.3444; p=0.7353
excluded 15330